OKLAHOMA CITY – The Oklahoma House of Representatives has passed legislation aimed at reducing insulin costs and improving access to affordable prescription drugs through a new state-run program. House Bill 1380, authored by Rep. Eddy Dempsey, R-Valliant, was approved with a 77-13 vote and now moves to the Senate for further consideration.
The bill seeks to ensure that Oklahomans do not have to ration or forgo insulin due to its high cost. By fostering competition and partnerships, the legislation aims to drive down prices and create a more reliable supply of insulin for those who depend on it.
If enacted, HB1380 would establish the Insulin Access and Affordability Program within the State Department of Health (OSDH). The program is designed to increase marketplace competition, reduce insulin prices, and address shortages of generic prescription drugs. It would grant OSDH the authority to enter agreements with nonprofit pharmaceutical companies and collaborate with nonprofit organizations to support these efforts.
Dempsey, who is diabetic, has personally experienced the financial burden of insulin costs and has witnessed its devastating impact. He has also lost a close friend to diabetes, an individual he believes could have benefited from this legislation.
“For many Oklahomans, insulin remains unaffordable or difficult to obtain,” Dempsey said. “This bill represents an opportunity to change that and prevent families from experiencing the tragic loss of a loved one due to lack of access to this critical medication.”
The legislation would allow OSDH to establish agreements with nonprofit entities to support the production and distribution of insulin, ensuring affordability and a stable supply for residents.
HB1380 now moves to the Senate for further deliberation. If passed and signed into law, it will take effect on July 1.
